These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18383843)

  • 41. [Locally advanced pancreatic cancer that enlarged after administration of gemcitabine and responded to oral TS-1--a case report].
    Tanaka S; Fujii M; Goubaru M; Ohta T; Ogata M; Makino Y
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1485-7. PubMed ID: 16227755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
    Suzuki S; Ozaki Y; Saida S; Kaji S; Koike N; Harada N; Hayashi T; Suzuki M
    Hepatogastroenterology; 2013 Jun; 60(124):916-20. PubMed ID: 23478143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
    Miyake T; Honma Y; Urano T; Kato N; Suzumiya J
    Int J Oncol; 2015 Jul; 47(1):315-24. PubMed ID: 25936828
    [TBL] [Abstract][Full Text] [Related]  

  • 44. S-1 in the treatment of pancreatic cancer.
    Sudo K; Nakamura K; Yamaguchi T
    World J Gastroenterol; 2014 Nov; 20(41):15110-8. PubMed ID: 25386059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine as second-line chemotherapy].
    Kawamoto K; Yamaguchi K; Okabe M; Tsuruta A; Morimoto Y; Niwano M; Sano K; Paku T; Imai S; Yoshida Y; Ito T; Ogasahara K
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1131-4. PubMed ID: 17637556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
    Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
    J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.
    Kurata N; Fujita H; Ohuchida K; Mizumoto K; Mahawithitwong P; Sakai H; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
    Int J Oncol; 2011 Aug; 39(2):473-82. PubMed ID: 21617862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
    Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
    Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
    Sasajima J; Tanno S; Koizumi K; Nakano Y; Habiro A; Chiba A; Fujii T; Sugiyama Y; Nakamura K; Nishikawa T; Mizukami Y; Okumura T; Kohgo Y
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1657-61. PubMed ID: 19838023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
    Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
    Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
    Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
    Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
    Prudner BC; Rathore R; Robinson AM; Godec A; Chang SF; Hawkins WG; Hirbe AC; Van Tine BA
    Clin Cancer Res; 2019 Aug; 25(16):5122-5134. PubMed ID: 31113844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
    Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
    Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
    Farrell JJ; Elsaleh H; Garcia M; Lai R; Ammar A; Regine WF; Abrams R; Benson AB; Macdonald J; Cass CE; Dicker AP; Mackey JR
    Gastroenterology; 2009 Jan; 136(1):187-95. PubMed ID: 18992248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
    Tu MJ; Ho PY; Zhang QY; Jian C; Qiu JX; Kim EJ; Bold RJ; Gonzalez FJ; Bi H; Yu AM
    Cancer Lett; 2019 Feb; 442():82-90. PubMed ID: 30389433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
    Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q
    Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.